Benitec Biopharma Limited (BNTC)

Last Closing Price: 2.96 (2024-02-20)

Company Description

Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $0.08M
Net Income (Most Recent Fiscal Year) $-19.56M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.49
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -35754.10%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -204.34%
Return on Assets (Trailing 12 Months) -142.81%
Current Ratio (Most Recent Fiscal Quarter) 3.62
Quick Ratio (Most Recent Fiscal Quarter) 3.62
Debt to Common Equity (Most Recent Fiscal Quarter) 0.01
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $5.97
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) --
Stock
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 2.59M
Free Float 2.48M
Market Capitalization $7.72M
Average Volume (Last 20 Days) 7898.80
Beta (Past 60 Months) 0.88
Percentage Held By Insiders (Latest Annual Proxy Report) 4.30%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%